Kirby McInerney LLP | Financial Litigation Law Firm | <h3 >Silverback Therapeutics, Inc.</h3 >
This links to the home page
Cases
PRACTICE AREAS

Silverback Therapeutics, Inc.


The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Western District of Washington, Seattle Division on behalf of those who acquired Silverback Therapeutics, Inc. (“Silverback” or the “Company”) (NASDAQ: SBTX) securities (a) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Offering Documents”) issued in connection with the Company’s initial public offering conducted on or about December 3, 2020 (the “IPO” or “Offering”); and/or (b) between December 3, 2020 and September 10, 2021, inclusive (the “Class Period”). Investors have until January 4, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
 
Silverback, a clinical-stage biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The Company’s lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers.
 
Pursuant to the Offering Documents, Silverback conducted the IPO, issuing 11.5 million shares of common stock priced at $21.00 per share.
 
On September 13, 2021, Silverback issued a press release “announc[ing] that interim data from the dose-escalation portion of its Phase 1/1b clinical trial evaluating SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced or metastatic HER2-expressing or amplified solid tumors will be presented at the upcoming European Society for Medical Oncology (ESMO) 2021 Congress from September 16-21, 2021[CK1] ” and advising that “[t]he accepted abstract . . . is now available on the ESMO website.” Per the accepted abstract (the “Abstract”), while there was a manageable safety profile for the Company’s experimental therapy, SBT6050 yielded only one partial response among 14 HER2-positive solid tumors. On this news, Silverback’s stock price declined by $4.54 per share, or approximately 23.35%, from $19.44 per share to close at $14.90 per share on September 13, 2021.

As of the time this Complaint was filed, the price of Silverback common stock continues to trade below the $21.00 per share Offering price, damaging investors.
 
The lawsuit alleges that, the Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (i) Silverback’s lead product candidate SBT6050 was less effective than the Company had represented to investors; (ii) accordingly, the Company had overstated SBT6050’s commercial and/or clinical prospects; and (iii) as a result, the Offering Documents and Defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.
 

Silverback Therapeutics, Inc. Investor Contact Form